KRAS and cancer: Next, we explored the potential contribution of Id1 to the acquired resistance to trametinib-mediated apoptosis, a core mechanism of trametinib-mediated cancer cell death [42, 43], in TR KRAS-mutant mouse and human LUAD cells.